Oncology Best Practice™: Integrating Oral Chemotherapy Formulations in Breast Cancer Care

Oncology Best Practice™: Integrating Oral Chemotherapy Formulations in Breast Cancer Care

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at [email protected] or call (609) 325-4668

Overview

Oncology Best Practice™ is a nationwide series of live, regional activities held in locations across the US deemed to have the highest educational need. This educational series will focus on the incorporation of recent practice-changing evidence on oral chemotherapeutic formulations by multidisciplinary teams in the context of managing real-world clinical scenarios. Chemotherapy has been the foundation of breast cancer care for decades, with great impact on survival outcomes with combination chemotherapy, dose-dense chemotherapy, and metronomic chemotherapy regimens. These benefits come at a price, however, with adverse events, such as infusion-related reactions, peripheral neuropathy, and alopecia, that are associated with intravenous administration of these drugs. Even with all the advances in other classes of drugs for treating breast cancer, chemotherapy is still the mainstay. The time has come for the development of innovative platforms for convenient oral chemotherapy delivery that allow for the continued use of these agents with improved safety profile and better quality of life for patients. The activity will use a variety of teaching modalities, including didactic presentation of new data, clinical scenarios exploring how oral chemotherapy may improve patient care and quality of life, strategies for navigating patient education and adherence, and peer-to-peer and peer-to-expert interactions. We look forward to you joining us to learn how to bring the latest innovative cancer treatment strategies to your patients.

Benefits of Attending

• Review the clinical data evaluating emerging oral chemotherapies compared with standard IV chemotherapies that may be available for your patients with breast cancer in the near future
• Learn how the experts and your peers are managing challenging cases for their patients eligible for oral chemotherapy regimens
• Ask the experts about best practices for mitigating adverse events related to oral chemotherapies

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Athenex.

Target Audience

This activity is directed toward medical oncologists, surgical oncologists, and radiation oncologists who treat or manage patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Discuss that rationale supporting the role of oral chemotherapeutic formulations in the treatment of patients with breast cancer
• Review data from recent clinical trials evaluating efficacy and safety of oral chemotherapeutic formulations in breast cancer treatment
• Examine strategies for optimizing treatment outcomes and patient selection for oral chemotherapeutic regimens
• Discuss effective strategies to proactively counsel and manage adverse events associated with chemotherapy in the treatment of patients with breast cancer

Chair

Hope Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California / Helen Diller Family Comprehensive Cancer Center
San Francisco, CA